Skip to content

Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]

Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01879878
Acronym
POUDER
Enrollment
40
Registered
2013-06-18
Start date
2013-12-31
Completion date
2015-12-31
Last updated
2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Ductal Adenocarcinoma

Keywords

pancreatic adenocarcinoma, broccoli sprouts, sulforaphane, palliative chemotherapy, cancer stem cells

Brief summary

The goal of the POUDER trial is to determine the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced pancreatic ductal adenocarcinoma that receive palliative chemotherapy.

Detailed description

Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.

Interventions

DIETARY_SUPPLEMENTVerum, broccoli sprout grain

Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.

DIETARY_SUPPLEMENTplacebo

Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.

Sponsors

German Cancer Research Center
CollaboratorOTHER
Heidelberg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Advanced, surgically non-treatable pancreatic ductal adenocarcinoma (surgical exploration, intraoperative biopsy but also palliative bypass interventions (bileodigestive anastomosis and/or gastroenterostomy because of preoperative cholestasis or impaired gastric emptying due to tumor-mass effect) * Intact gastric emptying * Written informed consent * Patients ≥18 years of age * Palliative chemotherapy

Exclusion criteria

* Intolerance to broccoli or its ingredients * Impaired mental status or language problems / barriers

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of a randomized controlled trialOne yearMain objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy

Secondary

MeasureTime frameDescription
Disease status (imaging and tumor markers)One yearDisease status (cancer progress or regress): CT-imaging staging (if available) and serum tumor markers (CEA and CA-19-9) peaks as additional parameters that provide insight into disease status.

Other

MeasureTime frameDescription
Substance bioavailabilityOne yearUrine analysis as marker of substance systemic bioavailability (conversion of the precursor glucoraphanin to the active drug substance sulforaphane). Urine analysis serves as control of the regular intake of the test substance as well.

Countries

Germany

Contacts

Primary ContactPeter Schemmer, Prof. Dr. med.
peter.schemmer@med.uni-heidelberg.de+49 6221 566205
Backup ContactVladimir J. Lozanovski, M.D.
vladimir.lozanovski@med.uni-heidelberg.de+49 6221 5636439

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026